- Home
- SNT vs INKT Comparison
SNT vs INKT Comparison
Compare SNT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNT | INKT |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 70.6M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNT | INKT |
|---|---|---|
| Price | $2.76 | $10.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 15.3K | ★ 23.5K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $6.80 |
| 52 Week High | $5.34 | $76.00 |
Technical Indicators
Market Signals| Indicator | SNT | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 44.63 |
| Support Level | $2.54 | $9.47 |
| Resistance Level | $2.90 | $12.40 |
| Average True Range (ATR) | 0.13 | 0.72 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 36.11 | 45.16 |
Price Performance
Historical ComparisonAbout SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.